New hope for advanced lung cancer: experimental combo therapy enters human trials
NCT ID NCT07414953
First seen Feb 19, 2026 · Last updated May 25, 2026 · Updated 17 times
Summary
This early-phase study tests a new drug called HS-10504 combined with other treatments in 400 people with advanced non-small cell lung cancer that has worsened after prior therapy. The goal is to find safe and effective doses and see how well the combination shrinks tumors. Participants must have specific genetic mutations (EGFR or MET) and be in fairly good health otherwise.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.